Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab in Patients With Advanced Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Xiaoyao Tian, MD
- Phone Number: 13514257836
- Email: xiaoyao_tian@junshipharma.com
Study Locations
-
-
-
Beijing, China, 100029
- Cancer Hospital of Chinese Academy of Medical Sciences
-
-
Jilin
-
Changchun, Jilin, China, 130012
- Jilin cancer hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Sign the informed consent form voluntarily;
- Age greater than or equal to 18 years old at time of signing informed consent, males and females are included;
- Expected survival time is greater than or equal to 3 months;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Pathologically confirmed locally advanced (Stage III B/C), metastatic or recurrent (Stage IV) non-small cell lung cancer (NSCLC);
- Pathologically confirmed extensive-stage small cell lung cancer (ES-SCLC, according to the Veterans Administration Lung Study Group (VALG) staging system);
- At least one measurable lesion as a target lesion (RECIST v1.1 criteria);
- Agree to provide tumor tissue samples (provide fresh biopsy samples before treatment as far as possible,provide archived samples within 2 years for patients who cannot provide fresh biopsy samples before treatment;
- The subject has good organ function as indicated by screening laboratory results;
- Males of reproductive potential or females of childbearing potential must use effective contraceptive methods (such as oral contraceptives, intrauterine device or barrier method combined with spermicide) during the trial and continue contraception for 6 months after the end of treatment;
- Good compliance and cooperated with the follow-up;
Exclusion Criteria:
- Within 2 years prior to enrollment, had other active neoplasm malignancies except for the study disease, but excluding neoplasm malignancies expected to be cured after treatment (including but not limited to thyroid cancer, carcinoma cervix in situ, basal or squamous cell skin carcinoma, or ductal carcinoma in situ after radical surgery after adequate treatment);
- Patients previously treated with anti-BTLA or anti-HVEM antibodies;
- Patients previously discontinued treatment due to PD-1/PD-L1 inhibitor toxicity;
- Adverse reaction caused by prior treatment that has not recovered to CTCAE Grade 1 and below (except Grade 2 toxicity that is long-lasting, not recoverable, and does not increase safety risk);
- Received allogeneic hematopoietic stem cell transplantation or solid organ transplantation in the past;
- A large amount of hydrothorax or ascites or pericardial effusion with clinical symptoms or requiring symptomatic treatment;
- Known history of Lung disorder: history of Interstitial pneumonia/drug-induced interstitial Pneumopathy or pneumonia, symptomatic Bronchospasm;
- Active infection requiring systemic therapy;
- A positive result for human immunodeficiency virus (HIV) antibody test;
- Known active tuberculosis (TB). For patients with suspicion of active TB should perform the test of chest X-ray, sputum, clinical signs and symptoms to exclude;
- Have a history of psychotropic drug abuse and unable to withdraw or have mental disorders;
- Pregnant or lactating woman;
- Known to be allergic to JS004 or toripalimab and its components;
- Other severe, acute or chronic medical or psychiatric disorders or laboratory abnormalities that, in the investigator's opinion, may increase the risk associated with study participation or may interfere with the interpretation of study results;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: JS004 200 mg in combination with toripalimab 240 mg was administered every 3 weeks as planned
|
Usage and dosage: 200mg of JS004 combined with 240mg of JS001 is given every 3 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The incidence of adverse events (AE) and serious adverse events (SAE) were assessed
Time Frame: 2 years
|
Incidence and severity of adverse events (AE) and serious adverse events (SAE) as assessed according to NCI-CTCAE 5.0, as well as abnormalities in vital signs, electrocardiogram, and laboratory tests
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PFS
Time Frame: 2 years
|
Progression-free survival
|
2 years
|
|
OS
Time Frame: 2 years
|
Duration of Response
|
2 years
|
|
DOR
Time Frame: 2 years
|
Duration of Response
|
2 years
|
|
DCR
Time Frame: 2 years
|
Disease Control Rate
|
2 years
|
|
Cmax
Time Frame: 2 years
|
Maximum Plasma Concentration
|
2 years
|
|
Tmax
Time Frame: 2 years
|
Time to Cmax
|
2 years
|
|
AUC0-t
Time Frame: 2 years
|
Area under the concentration versus time curve from time 0 to the last measurable concentration
|
2 years
|
|
AUC0-inf
Time Frame: 2 years
|
AUC from time 0 to infinity
|
2 years
|
|
Kel
Time Frame: 2 years
|
Elimination rate constant
|
2 years
|
|
t1/2
Time Frame: 2 years
|
Elimination half life time
|
2 years
|
|
CL/F
Time Frame: 2 years
|
Clearance
|
2 years
|
|
Vd/F
Time Frame: 2 years
|
Apparent volume of distribution
|
2 years
|
|
Rac
Time Frame: 2 years
|
Accumulation factor
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- JS004-006-I/II-LC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.